Source-backed trade-policy analysis for import-scope decisions. Start from a product line, origin, supplier, or case, then move from public record to operating posture.
A 100 percent DST tariff threat points to Section 301, but collection still needs a USTR instrument, product scope, effective date, and HTS language.
Hormuz hands the administration a supply-chain-security story, but helium sits outside the current Section 232 tariff architecture. The docket the shock reinforces is Section 301, not 232.
Section 301 supplies the tariff power IEEPA lacked. The German drug-pricing case is weak instead on statutory fit and the causal chain to U.S. commerce.
Not yet a Section 301 tariff. USTR has opened the drug-pricing record, but the live duty exposure remains Proclamation 11020's Section 232 regime.
Parliament approved the EU side of Turnberry on June 16, 2026, but built the cuts to be reversible, so a calendar of EU suspension triggers governs the deal.
The Beijing summit produced a framework deal, not a tariff change. The Section 301, 122, and 232 stack on Chinese-origin goods stands unchanged after May 15.